Patents by Inventor J. Gordon Adamson

J. Gordon Adamson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hemoglobin-Targeted Drug Delivery For The Treatment of Cancer
    Publication number: 20230190947
    Abstract: The use of hemoglobin as a targeting carrier for drugs is disclosed. Such hemoglobin-drug complexes have utility in the treatment of cancer, in particular cancers of the liver and colon. Said drug is preferably a nucleoside analog, in particular floxuridine and is covalently attached to the hemoglobin in a molar drug ratio of between 1 and 20.
    Type: Application
    Filed: June 21, 2017
    Publication date: June 22, 2023
    Inventors: Steven Brookes, J. Gordon Adamson, David Bell
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF HISTIOCYTOSIS
    Publication number: 20160158368
    Abstract: The present application provides methods of treating CD163+ histiocytosis comprising administering an effective amount of a CD163 ligand-drug conjugate to an animal or cell in need thereof.
    Type: Application
    Filed: October 30, 2015
    Publication date: June 9, 2016
    Inventors: Irina Ayres, Murray J. Cutler, Kathryn Matthews, Steven Brookes, J. Gordon Adamson, David N. Bell
  • TARGETED DELIVERY OF ANTIVIRAL COMPOUNDS THROUGH HEMOGLOBIN BIOCONJUGATES
    Publication number: 20120213732
    Abstract: This invention relates to targeted delivery of anti-viral compounds through protein bioconjugation. More particularly, it relates to an anti-viral compound conjugated to a protein, such as hemoglobin and to a method of treating a viral infection using said conjugate. The invention also provides a method of targeted drug delivery of an anti-viral nucleoside analogue to macrophages, cells comprising a hemoglobin receptor and to CD163 bearing cells.
    Type: Application
    Filed: February 17, 2012
    Publication date: August 23, 2012
    Applicant: Therapure Biopharma Inc.
    Inventors: J. Gordon Adamson, David Bell, Nancy Ng, Petrus Biessels
  • Hemoglobin-haptoglobin complexes
    Publication number: 20090023632
    Abstract: Construct-complexes of a hemoglobin, a hepatocyte modifying substance bound to the hemoglobin, and a haptoglobin bound to the hemoglobin, are provided, for administration to mammalian patients. The construct-complex may be formed ex vivo, or a hemoglobin-hepatocyte modifying substance combination may be administered to the patient so that haptoglobin in the mammalian body bonds thereto to form the construct-complex in vivo. Disorders of the liver may be diagnosed and treated using construct-complexes described herein.
    Type: Application
    Filed: April 17, 2006
    Publication date: January 22, 2009
    Applicant: Hemosol, Inc.
    Inventors: J. Gordon Adamson, Jolanta M. Wodzinska, M. S. Moore
  • Hemoglobin-haptoglobin complexes
    Publication number: 20030013642
    Abstract: Construct-complexes of a hemoglobin, a hepatocyte modifying substance bound to the hemoglobin, and a haptoglobin bound to the hemoglobin, are provided, for administration to mammalian patients. The construct-complex may be formed ex vivo, or a hemoglobin-hepatocyte modifying substance combination may be administered to the patient so that haptoglobin in the mammalian body bonds thereto to form the construct-complex in vivo. Disorders of the liver may be diagnosed and treated using construct-complexes described herein.
    Type: Application
    Filed: August 30, 2002
    Publication date: January 16, 2003
    Applicant: Hemosol, Inc.
    Inventors: J. Gordon Adamson, Jolanta M. Wodzinska, M.S. Celine Moore
  • Hemoglobin-haptoglobin complexes
    Patent number: 6479637
    Abstract: Construct-complexes of a hemoglobin, a hepatocyte modifying substance bound to the hemoglobin, and a haptoglobin bound to the hemoglobin, are provided, for administration to mammalian patients. The construct-complex may be formed ex vivo, or a hemoglobin-hepatocyte modifying substance combination may be administered to the patient so that haptoglobin in the mammalian body bonds thereto to form the construct-complex in vivo. Disorders of the liver may be diagnosed and treated using construct-complexes described herein.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: November 12, 2002
    Assignee: Hemsol Inc.
    Inventors: J. Gordon Adamson, Jolanta Maria Wodzinska, M. S. Celine Moore